IL-6 stimulates tumour macrophage infiltration in ovarian cancer, and recently it has been shown that this action can be inhibited by the neutralizing anti-IL-6 antibody siltuximab in preclinical and clinical studies [65]. The gene discussed is IL6; the disease is neoplasm.